



## Cerebral vasculopathy in patients with sickle cell disease and stroke: now you see it, now you don't

by Miguel R. Abboud

*Received: April 22, 2024.*

*Accepted: May 8, 2024.*

*Citation: Miguel R. Abboud. Cerebral vasculopathy in patients with sickle cell disease and stroke: now you see it, now you don't.*

*Haematologica. 2024 May 16. doi: 10.3324/haematol.2024.285383 [Epub ahead of print]*

### *Publisher's Disclaimer.*

*E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication.*

*E-publishing of this PDF file has been approved by the authors.*

*After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors' final approval; the final version of the manuscript will then appear in a regular issue of the journal.*

*All legal disclaimers that apply to the journal also pertain to this production process.*

Cerebral vasculopathy in patients with sickle cell disease and stroke: now you see it, now you don't

Miguel R. Abboud

Department of Pediatrics and Adolescent Medicine, American University of Beirut, Beirut, Lebanon

Corresponding author: Miguel R. Abboud – e-mail address [abboudm@aub.edu.lb](mailto:abboudm@aub.edu.lb)

Strokes are one of the most devastating complications of sickle cell disease (SCD). Until recently SCD was the main cause of ischemic strokes in children in the US and many other countries. After the development of an ischemic stroke children have to be placed on chronic transfusions to prevent a recurrence although the risk may be lower if the stroke occurred during another acute event (1). The incidence of ischemic strokes was significantly reduced after the advent of transcranial doppler (TCD) screening and the institution of transfusion therapy for primary prevention in children found to be at high risk. More recently hydroxyurea was shown to be equally effective in primary stroke prevention in children with abnormal TCD both in the setting of high-income countries as well as sub-Saharan Africa (2). Stem cell transplantation is also effective in secondary prevention in children who already had a stroke as well as primary prevention in children with abnormal TCD. The epidemiology was defined in seminal study of a large number of patients which showed that ischemic strokes were more prevalent in the first decade of life and the vast majority of patients had either homozygous sickle cell anemia (HbSS) or heterozygous HbSbeta<sup>0</sup> thalassemia, with few if any strokes occurring in patients with Hb SC (3). As a result, most studies have since focused on the first two genotypes, and little is published about strokes in other genotypes. The pathophysiology of cerebral ischemic strokes remains somewhat of a mystery. Originally thought to be caused by small vessel vasculopathy these events were demonstrated to be due to large arterial vasculopathy in the anterior cerebral circulation and the vessels of the circle of Willis by Stockman, et al. (4) and others. Why the posterior circulation is relatively spared and what are the drivers for stroke risk also remain unknown. Furthermore, recent studies, using techniques like MRA demonstrate that 30-40% of children with ischemic strokes do not have demonstrable cerebral arterial stenosis (5).

In the study in the current issue of *Haematologica*, Linguet and colleagues (6) describe strokes that occurred over a period of 13 years in a group of over 1500 children with sickle cell disease at a comprehensive center in France. Relatively few strokes were reported in this group, who had access to TCD screening. Of a total of 25 affected children 12 had what the authors refer to as atypical strokes without evidence of cerebral arteriopathy. These patients were older and 25% had a hemoglobin SC genotype. Despite the small number of patients important themes emerged from this study: The first theme is that these atypical strokes occur in the setting of other complications of SCD. These included fat embolism syndrome, a complication that seems to be more common in patients with HbSC (7), sepsis and acute chest syndrome as well as ICU admission. The inability of the cerebral

circulation to adapt to changing needs for oxygen has been reported in SCD but this has not been studied in the context of exacerbated responses and vasoconstriction secondary to other insults and acute complications. This issue is worthy of further investigation. With increased accessibility of TCD a higher proportion of strokes are likely to occur in the setting of acute events in patients with normal TCD at screening. While these strokes may not require long term transfusion for secondary prevention as shown in the current study, prevention may be possible by prompt management of the initial event, for example by initiating exchange transfusion followed by therapeutic plasma exchange early for fat embolism (7).

The second theme is that the posterior circulation was involved in several patients. While typically spared in ischemic strokes the posterior circulation is not normal in SCD. The fact that the cerebral blood flow is increased in SCD to keep up with oxygen demand may render many segments of the brain relatively ischemic and liable to damage during acute events. The posterior circulation has been shown to have increased cerebral blood velocities and cerebral blood flow (8,9) in patients with SCD the significance of this should be further explored. Furthermore, SCD is a known risk for posterior reversible encephalopathy syndrome (PRES), several factors have been invoked to explain the failed cerebral auto regulation and endothelial dysfunction in this setting (10).

The third theme refers to the deleterious impacts of certain treatment modalities used in SCD. First among these are corticosteroids the uses of which has been associated with multiple complications of sickle in sickle cell disease, including the precipitation of painful crises, hemorrhagic strokes, and now ischemic strokes. Thus, caution is urged when these agents must be used and patients should be adequately prepared, otherwise alternative therapies should be considered, for example rituximab and IVIG in delayed hemolytic transfusion reactions. Attention should also be paid to the role of hyperviscosity in SCD. This is often ignored and the consequences, as demonstrated here, may be dire. While it is unclear how to mitigate the risk of hyperviscosity in acute settings, judicious use of transfusions, exchange transfusions and in some cases, phlebotomy is recommended to prevent hyper viscosity from developing.

Finally, as described in a recent editorial to an issue of *Frontiers in Physiology*, in SCD there is "evidence of local ischemia despite global hyperemia" in the brain. Arteriopathy, may however only be seen after its deleterious effects become manifest or by using appropriate techniques that are still not well developed for clinical use. The pathology is always there but, as in the magician's adage, "now you see it, now you don't".

## **References:**

- 1- Scothorn DJ, Price C, Schwartz D, et al. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. *J Pediatrics*. 2002;140(3):348-354.
- 2- Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to hydroxyurea (twitch): A Multicentre, open-label, phase 3, non-inferiority trial. *Lancet*. 2016;387(10019):661-670.
- 3- Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. *Blood*. 1998;91(1):288-294.
- 4- Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large cerebral vessels in sickle-cell anemia. *N Engl J Med*. 1972;287(17):846-849.
- 5- Helton KJ, Adams RJ, Kesler KL, et al. Magnetic Resonance Imaging/angiography and transcranial doppler velocities in sickle cell anemia: Results from the switch trial. *Blood*. 2014;124(6):891-898.
- 6- Linguet SL, Verlhac S, Missud F, et al. Stroke without cerebral arteriopathy in sickle cell disease children: what causes? what treatment? *Haematologica*. xxx
- 7- Tsitsikas DA, May JE, Gangaraju R, Abukar J, Amos RJ, Marques MB. Revisiting fat embolism in sickle syndromes: Diagnostic and emergency therapeutic measures. *Br J Haematol*. 2019;186(4):e112-e115.
- 8- Kawadler JM, Hales PW, Barker S, Cox TC, Kirkham FJ, Clark CA. Cerebral perfusion characteristics show differences in younger versus older children with sickle cell anaemia: Results from a multiple-inflow-time arterial spin labelling study. *NMR in Biomed*. 2018;31(6):e3915.
- 9- Adegoke SA, Figueiredo MS, Vicari P, et al. Posterior circulation evaluation in patients with sickle cell anemia. *J Stroke Cerebrovasc Dis*. 2016;25(3):717-721.
- 10- Solh Z, Taccobe MS, Marin S, Athale U, Breakey VR. Neurological PRESentations in sickle cell patients are not always stroke: A review of posterior reversible encephalopathy syndrome in sickle cell disease. *Pediatr Blood Cancer*. 2016;63(6):983-989.